# Monte Rosa Therapeutics Inc. (GLUE)

Source: https://www.quantisnow.com/company/GLUE
Generated: 2026-11-10T12:36:39.662Z

- Ticker: GLUE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001826457

## Latest GLUE news and filings

- 2026-11-09 12:00 UTC [Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout](https://www.quantisnow.com/insight/monte-rosa-therapeutics-presents-preclinical-data-at-acr-convergence-2026-6780083)
- 2026-11-05 12:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-monte-rosa-therapeutics-inc-6774610)
- 2026-11-05 12:02 UTC [SEC Form 8-K] [Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/monte-rosa-therapeutics-inc-filed-sec-form-8-k-results-of-6774526)
- 2026-11-05 12:00 UTC [Earnings] [Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-third-quarter-2026-financial-results-and-6774461)
- 2026-11-03 21:01 UTC [Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/monte-rosa-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-6769322)
- 2026-11-02 12:00 UTC [Conference Announcement] [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-6765997)
- 2026-10-28 11:00 UTC [Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-second-phase-6760373)
- 2026-10-06 20:05 UTC [SEC Form 4] [Principal Accounting Officer Bowen Matthew sold $137 worth of shares (13 units at $10.56) (SEC Form 4)](https://www.quantisnow.com/insight/principal-accounting-officer-bowen-matthew-sold-137-worth-of-shares-6738855)
- 2026-10-02 20:01 UTC [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6734217)
- 2026-10-01 12:43 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Monte Rosa Therapeutics with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-monte-rosa-therapeutics-with-a-6731666)
- 2026-10-01 11:38 UTC [SEC Form 8-K] [Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/monte-rosa-therapeutics-inc-filed-sec-form-8-k-regulation-fd-6731414)
- 2026-10-01 11:00 UTC [Earnings Date] [Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-6731317)
- 2026-09-30 20:01 UTC [Earnings Date] [Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk](https://www.quantisnow.com/insight/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-6730528)
- 2026-09-08 11:02 UTC [SEC Form 8-K] [Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/monte-rosa-therapeutics-inc-filed-sec-form-8-k-regulation-fd-6707393)
- 2026-09-08 11:00 UTC [Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-initiation-of-6707363)
- 2026-09-02 20:01 UTC [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6702962)
- 2026-09-01 11:00 UTC [Conference Announcement] [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-6700456)
- 2026-08-24 11:00 UTC [Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-6692027)
- 2026-08-14 20:23 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-monte-rosa-therapeutics-6683136)
- 2026-08-06 11:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-monte-rosa-therapeutics-inc-6667211)
- 2026-08-06 11:04 UTC [SEC Form 8-K] [Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/monte-rosa-therapeutics-inc-filed-sec-form-8-k-results-of-6667159)
- 2026-08-06 11:00 UTC [Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates](https://www.quantisnow.com/insight/monte-rosa-therapeutics-announces-second-quarter-2026-financial-results-and-6667070)
- 2026-07-17 20:05 UTC [SEC Form 4] [President & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-warmuth-markus-sold-220219-worth-of-shares-9500-6640978)
- 2026-07-16 20:10 UTC [SEC Form 4] [Chief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-champoux-jennifer-exercised-4351-shares-at-a-6639726)
- 2026-07-08 15:28 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-monte-rosa-therapeutics-6631319)
- 2026-07-07 20:41 UTC [SEC Form 4] [Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $139,849 worth of shares (6,000 units at $23.31) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-townson-sharon-exercised-6000-shares-at-a-6630286)
- 2026-07-06 21:57 UTC [SEC Form 4] [Director Behbahani Ali disposed of 1,015,000 shares and acquired 15,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-behbahani-ali-disposed-of-1015000-shares-and-acquired-15000-6628958)
- 2026-07-06 21:51 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-monte-rosa-therapeutics-6628942)
- 2026-07-02 20:01 UTC [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6624965)
- 2026-07-01 20:57 UTC [SEC Form 4] [Chief Medical Officer Janku Filip exercised 5,407 shares at a strike of $13.41 and sold $132,472 worth of shares (5,407 units at $24.50) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-janku-filip-exercised-5407-shares-at-a-6623430)
- 2026-06-30 20:05 UTC [SEC Form 4] [Chief Medical Officer Janku Filip exercised 6,000 shares at a strike of $7.56 and sold $137,700 worth of shares (6,000 units at $22.95) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-janku-filip-exercised-6000-shares-at-a-6620767)
- 2026-06-30 20:05 UTC [SEC Form 4] [Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $231,100 worth of shares (10,000 units at $23.11) (SEC Form 4)](https://www.quantisnow.com/insight/director-manning-anthony-m-exercised-10000-shares-at-a-strike-6620766)
- 2026-06-29 20:02 UTC [SEC Form 144] [SEC Form 144 filed by Monte Rosa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-monte-rosa-therapeutics-inc-6618858)
- 2026-06-25 20:05 UTC [SEC Form 4] [Chief Medical Officer Janku Filip exercised 36,000 shares at a strike of $7.56 and sold $882,203 worth of shares (41,845 units at $21.08) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 59,992 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-janku-filip-exercised-36000-shares-at-a-6615748)
- 2026-06-25 20:05 UTC [SEC Form 4] [Chief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $60,000 worth of shares (3,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-townson-sharon-exercised-3000-shares-at-a-6615744)
- 2026-06-25 20:05 UTC [SEC Form 4] [Chief Operating Officer Champoux Jennifer sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan and exercised 2,175 shares at a strike of $3.98 (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-champoux-jennifer-sold-43500-worth-of-shares-6615742)
- 2026-06-18 20:05 UTC [SEC Form 4] [Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-champoux-jennifer-exercised-2176-shares-at-a-6608552)
- 2026-06-18 20:05 UTC [SEC Form 4] [Chief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $57,000 worth of shares (3,000 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-townson-sharon-exercised-3000-shares-at-a-6608520)
- 2026-06-12 22:44 UTC [SEC Form 4] [SEC Form 4 filed by Director Behbahani Ali](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-behbahani-ali-6601381)
- 2026-06-12 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Schiff Andrew N](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-schiff-andrew-n-6600177)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GLUE
- Earnings history: https://www.quantisnow.com/earnings/GLUE
- Dividend history: https://www.quantisnow.com/dividends/GLUE
- Insider transactions: https://www.quantisnow.com/insiders/GLUE
- Options chain: https://www.quantisnow.com/options/GLUE
- SEC 8-K filings only: https://www.quantisnow.com/company/GLUE/8-k
- RSS and alerts for GLUE: https://www.quantisnow.com/docs/rss-feeds.md